Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
European Hematology Association
Headquarters: The Hague, Netherlands
Website: http://www.ehaweb.org
Year Founded: 1992
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Jun 19, 2024
Product Development
Clinical Report: Zentalis hold resurfaces WEE1 safety concerns
Plus data from BioNTech, MediLink, Nurix, Aerovate and more
BioCentury | Jun 14, 2024
Finance
Public Equity Report: IPO action from QuantumPharm, Ascentage, Alumis, Telix
Plus: Fundraising by Avidity, Ultragenyx, ProKidney, Disc Medicine, Opthea and Replimmune
BioCentury | Jun 13, 2023
Management Tracks
June 13 Quick Takes: Alkermes, Sarissa trade messages ahead of proxy fight
Plus: Alladapt touts early food allergy data, Antios winds down, and updates from Gracell, Laronde, Range Bio and AZ
BioCentury | Apr 19, 2023
Finance
April 19 Quick Takes: Forbion’s largest-ever raise, $1.5B for two funds
Plus: SCOTUS punts mifepristone decision and updates from Legend, Vaxcyte and Roche
BioCentury | Feb 22, 2023
Data Byte
Sickle cell pipeline: not all gene therapies made the same
Permanently restoring hemoglobin is the goal, but companies have different ideas about how to achieve it
BioCentury | Dec 7, 2022
Product Development
Early sickle cell data show promise, as Editas refines its pipeline
Initial clinical data of EDIT-301, though limited, shed light on Editas gene editing platform
BioCentury | Jun 25, 2022
Discovery & Translation
Expanding the CAR T cell toolbox
Snapshots from the literature add to the growing picture of next-gen CAR T manipulations that could enhance multiple cancer therapies
BioCentury | Jun 17, 2022
Data Byte
Ex vivo mechanisms competing with exa-cel and beti-cel
Behind Vertex and CRISPR, at least four companies are inhibiting BCL11A for hemoglobinopathies
BioCentury | Jun 14, 2022
Data Byte
Epcoritamab shows best-in-class potential for DLBCL
Efficacy, safety in CAR T naive patients could challenge CD19 CAR Ts in diffuse large B cell lymphoma
BioCentury | Jun 14, 2022
Product Development
Vertex and CRISPR’s functional cure: room to improve?
The partners’ sickle cell and β-thalassemia data raise questions for competitors on mechanism, safety and price
Items per page:
1 - 10 of 201